Crescent Biopharma Financials - Benzinga

Crescent Biopharma Inc

CBIONASDAQ

Trade with Public

Trade with Public

$16.84

-0.05-0.3%

마지막 업데이트: Sep 18, 4:22 PM

개요 뉴스 실적 전망 이벤트 목표가재무심리 지분 현황 비교 옵션 주식 보고서

Crescent Biopharma Financials

Crescent Biopharma (CBIO) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Crescent Biopharma Q2 EPS $(0.74) Beats $(0.79) Estimate

Crescent Biopharma (NASDAQ:CBIO) reported quarterly losses of $(0.74) per share which beat the analyst consensus estimate of $(0.79) by 6.33 percent. This is a 84.99 percent increase over losses of $(4.93) per share

Benzinga Newsdesk

PRO
Crescent Biopharma Q1 EPS $(0.70) Beats $(0.98) Estimate, Sales $1.039M Beat $357.143K Estimate

Crescent Biopharma (NASDAQ:CBIO) reported quarterly losses of $(0.70) per share which beat the analyst consensus estimate of $(0.98) by 28.57 percent. This is a 96.43 percent increase over losses of $(19.63) per share

Benzinga Newsdesk

PRO
Crescent Biopharma Q4 EPS $(4.01) Misses $(2.31) Estimate, Sales $10.844M Beat $4.000M Estimate

Crescent Biopharma (NASDAQ:CBIO) reported quarterly losses of $(4.01) per share which missed the analyst consensus estimate of $(2.31) by 73.44 percent. This is a 79.69 percent increase over losses of $(19.74) per share

Benzinga Newsdesk

PRO
Crescent Biopharma Q3 EPS $(1.27) Beats $(1.98) Estimate

Crescent Biopharma (NASDAQ:CBIO) reported quarterly losses of $(1.27) per share which beat the analyst consensus estimate of $(1.98) by 35.92 percent.

Benzinga Newsdesk

PRO
Crescent Biopharma Q2 EPS $(4.93) Misses $(1.11) Estimate, Cash Balance Of $152.6M

Benzinga Newsdesk

PRO
Catalyst Biosciences Q2 EPS $1.64 Up From $(0.64) YoY

Catalyst Biosciences (NASDAQ:CBIO) reported quarterly earnings of $1.64 per share. This is a 356.25 percent increase over losses of $(0.64) per share from the same period last year.

Benzinga Newsdesk

© 2026 Benzinga | All Rights Reserved